Make DermaSensor™ Your New Assistant For Skin Cancer Care
We’ve launched the world’s first point-and-click device that brings objective skin cancer assessment to primary care offices. You now have a tool to help evaluate patient skin cancer risk in just seconds.
- Rapid, non-invasive skin cancer risk assessment by any trained team member
- Objective risk classification can improve your clinical decisions and confidence
- Augment your typical skin assessment routine and increase your reimbursement level
- Can help avoid benign excisions with unnecessary morbidity and poor reimbursement
Learn more about DermaSensor
Rapid Recording
Quick, point-and-click recordings collect and analyze non-visual spectral data quickly
Optical Spectroscopy
Light-emitting tip non-invasively scans the lesion, receiving and analyzing spectral data at the cellular level from below the skin's surface
Easy to Use
Wireless, ergonomic design makes the device intuitive to learn and easy to use
Immediate Result
DermaSensor's proprietary algorithm provides an instant, objective result to support your clinical decision at the point of care
Assess
Assess the patient's lesions to identify those visually suggestive of skin cancer for which an objective risk assessment would be helpful.
Analyze
Use DermaSensor to analyze those lesions of concern to receive a Higher Risk or Lower Risk result for each lesion.
Act
Counsel your patient on next steps, such as further investigating the lesion through a biopsy or specialist referral, or just monitoring the lesion having ruled out the need for an immediate biopsy or referral.
Simple Design.
Effortless Application
- Intuitive on-screen user interface guides you step-by-step through the evaluation
- Activate a recording using either the touch-screen interface or conveniently positioned side buttons
DermaSensor is not a camera or dermatoscope. DermaSensor uses pulses of light and elastic scattering spectroscopy to assess a lesion’s cellular and sub-cellular structures.
Safety and Efficacy Results for DERM-ASSESS II Prospective, Multi-Centre Study
Study reported no adverse events as well as no significant difference between DermaSensor's and dermatologists' sensitivity and specificity
DermaSensor's sensitivity for melanoma was 100.0%* while the study dermatologists' was 90.9%. For BCC and SCC, also known as Non-Melanoma Skin Cancer (NMSC), DermaSensor's sensitivity was 93.3% and the dermatologists' was 98.3%
DermaSensor Device and Dermatologist Sensitivity For Skin Cancers
Risks
False-positive and false-negative results may lead to unnecessary care or to a malignant skin lesion not being optimally managed, respectively. However, it is important to note that biopsy is used to confirm pathology and that elastic scattering spectroscopy is to be used as an adjunctive tool to visual inspection and history-taking. See all Claims and Substantiations©2020 DermaSensor, inc
